Real-world study: apremilast appears safe and effective for psoriasis in elderly patients

  • Phan C & al.
  • Drugs Aging
  • 21 Jul 2020

  • curated by Brian Richardson, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Apremilast is associated with good effectiveness and acceptable safety in patients with psoriasis aged ≥65 years, according to a retrospective, real-world study.

Why this matters

  • Real-world studies are needed for newly developed therapies, particularly in the elderly.

Key results

  • 45.2% of patients achieved a Physician’s Global Assessment score of 0 or 1 between 3 and 6 months after initiation.
  • 54.8% of patients stopped therapy:
    • 56.6% stopped for adverse events.
    • 23.7% stopped for primary failures.
    • 9.2% stopped for relapses.
  • Patients aged ≥75 years were more likely to discontinue because of adverse events (83.3%) compared with patients aged 65-74 years (45.3%; P=.007).
  • Patients aged ≥85 years had a significantly lower continuation rate compared with younger patients (P=.01).

Study design

  • 135 patients (mean age, 73.5 years) with psoriasis who received apremilast were included.
  • Funding: None.

Limitations

  • Retrospective.